Skip to main content

Advertisement

Fig. 4 | BMC Cancer

Fig. 4

From: Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

Fig. 4

Kaplan – Meier survival estimates of overall survival according to the EGFR amplification, PTEN deletion and MGMT methylation status and random assignment to Chemoradiotheraphy (CRT) or Radiotherapy (RT) in patients with GBM IDH-wildtype. The survival curves of glioma’s patients according to treatment received (a). The impact of EGFR amplification, PTEN deletion and MGMT methylation in radiotherapy response using GBM IDH-wildtype subgroup (b). The impact of EGFR amplification and MGMT methylation in chemo-radiotherapy response using GBM IDH-wildtype subgroup (c)

Back to article page